

Keith G Oldroyd

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6148379/publications.pdf>

Version: 2024-02-01

234
papers

26,629
citations

13827

67
h-index

6113

159
g-index

239
all docs

239
docs citations

239
times ranked

14298
citing authors

#	ARTICLE	IF	CITATIONS
1	Inhibition of myocardial cathepsin-L release during reperfusion following myocardial infarction improves cardiac function and reduces infarct size. <i>Cardiovascular Research</i> , 2022, 118, 1535-1547.	1.8	6
2	Recovery of platelet reactivity following cessation of either aspirin or ticagrelor in patients treated with dual antiplatelet therapy following percutaneous coronary intervention: a GLOBAL LEADERS substudy. <i>Platelets</i> , 2022, 33, 141-146.	1.1	7
3	Fractional Flow Reserveâ€“Guided PCI as Compared with Coronary Bypass Surgery. <i>New England Journal of Medicine</i> , 2022, 386, 128-137.	13.9	169
4	A Randomized, double-blind, dose ranging clinical trial of intravenous FDY-5301 in acute STEMI patients undergoing primary PCI. <i>International Journal of Cardiology</i> , 2022, 347, 1-7.	0.8	3
5	A Noncontrast CMR Risk Score for Long-Term Risk Stratification in Reperfused ST-Segment Elevation Myocardial Infarction. <i>JACC: Cardiovascular Imaging</i> , 2022, 15, 431-440.	2.3	8
6	Ticagrelor Monotherapy After PCI in High-Risk Patients With Prior MI. <i>JACC: Cardiovascular Interventions</i> , 2022, 15, 282-293.	1.1	6
7	Ticagrelor Monotherapy or Dual Antiplatelet Therapy After Drugâ€“Eluting Stent Implantation: Perâ€“Protocol Analysis of the GLOBAL LEADERS Trial. <i>Journal of the American Heart Association</i> , 2022, 11, e024291.	1.6	4
8	Safety and efficacy of ticagrelor monotherapy according to drug-eluting stent type: the TWILIGHT-STENT study. <i>EuroIntervention</i> , 2022, 17, 1330-1339.	1.4	5
9	Quality of Life After Fractional Flow Reserveâ€“Guided PCI Compared With Coronary Bypass Surgery. <i>Circulation</i> , 2022, 145, 1655-1662.	1.6	6
10	Bioabsorbable polymer drug-eluting stents with 4-month dual antiplatelet therapy versus durable polymer drug-eluting stents with 12-month dual antiplatelet therapy in patients with left main coronary artery disease: the IDEAL-LM randomised trial. <i>EuroIntervention</i> , 2022, 17, 1467-1476.	1.4	8
11	Clinical Outcomes According to ECG Presentations in Infarct-Related Cardiogenic Shock in the Culprit Lesion Only PCI vsâ€“Multivessel PCI in Cardiogenic Shock Trial. <i>Chest</i> , 2021, 159, 1415-1425.	0.4	4
12	Effect of coronary flow on intracoronary alteplase: a prespecified analysis from a randomised trial. <i>Heart</i> , 2021, 107, 299-312.	1.2	6
13	Ticagrelor Monotherapy Versus Dual-Antiplatelet Therapy After PCI. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 444-456.	1.1	27
14	Flow, pressure, anatomy: an eternal golden braid. <i>Cardiovascular Research</i> , 2021, 117, 1426-1427.	1.8	1
15	Thin Strut CoCr Biodegradable Polymer Biolimus A9-Eluting Stents versus Thicker Strut Stainless Steel Biodegradable Polymer Biolimus A9-Eluting Stents: Two-Year Clinical Outcomes. <i>Journal of Interventional Cardiology</i> , 2021, 2021, 1-7.	0.5	4
16	Safety and efficacy of Everolimusâ€“Eluting bioabsorbable Polymerâ€“Coated stent in patients with long coronary lesions: The EVOLVE 48 study. <i>Catheterization and Cardiovascular Interventions</i> , 2021, , .	0.7	2
17	Do we really understand how drug eluted from stents modulates arterial healing?. <i>International Journal of Pharmaceutics</i> , 2021, 601, 120575.	2.6	6
18	Distal Transradial (Snuffbox) Access for Coronary Catheterization: A Systematic Review. <i>Cardiology in Review</i> , 2021, 29, 210-216.	0.6	2

#	ARTICLE	IF	CITATIONS
19	Thermodilution-derived temperature recovery time: a novel predictor of microvascular reperfusion and prognosis after myocardial infarction. <i>EuroIntervention</i> , 2021, 17, 220-228.	1.4	6
20	A novel algorithm for the computation of the diastolic pressure ratio in the invasive assessment of the functional significance of coronary artery disease. <i>Panminerva Medica</i> , 2021, 63, 206-213.	0.2	2
21	Prevalence of Coronary Artery Disease and Coronary Microvascular Dysfunction in Patients With Heart Failure With Preserved Ejection Fraction. <i>JAMA Cardiology</i> , 2021, 6, 1130.	3.0	114
22	Post-stenting fractional flow reserve vs coronary angiography for optimization of percutaneous coronary intervention (TARGET-FFR). <i>European Heart Journal</i> , 2021, 42, 4656-4668.	1.0	79
23	Impact of Age on the Safety and Efficacy of Ticagrelor Monotherapy in Patients Undergoing PCI. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 1434-1446.	1.1	13
24	Influenza Vaccination After Myocardial Infarction: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial. <i>Circulation</i> , 2021, 144, 1476-1484.	1.6	121
25	Ticagrelor monotherapy in patients with chronic kidney disease undergoing percutaneous coronary intervention: TWILIGHT-CKD. <i>European Heart Journal</i> , 2021, 42, 4683-4693.	1.0	18
26	Comparison of risk prediction models in infarct-related cardiogenic shock. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 890-897.	0.4	11
27	Safety of Selective Intracoronary Hypothermia During Primary Percutaneous Coronary Intervention in Patients With Anterior STEMI. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 2047-2055.	1.1	15
28	Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR. <i>European Heart Journal</i> , 2021, 42, 4624-4634.	1.0	54
29	Risk Stratification Guided by the Index of Microcirculatory Resistance and Left Ventricular End-Diastolic Pressure in Acute Myocardial Infarction. <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e009529.	1.4	8
30	Impact of Center Volume on Outcomes in Myocardial Infarction Complicated by Cardiogenic Shock: A CULPRIT-ACS SHOCK Substudy. <i>Journal of the American Heart Association</i> , 2021, 10, e021150.	1.6	1
31	Sex differences in procedural and clinical outcomes following rotational atherectomy. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 95, 232-241.	0.7	24
32	1-Year Outcomes of Angina Management Guided by Invasive Coronary Function Testing (CorMicA). <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 33-45.	1.1	141
33	Percutaneous coronary angioplasty versus coronary artery bypass grafting in the treatment of unprotected left main stenosis: updated 5-year outcomes from the randomised, non-inferiority NOBLE trial. <i>Lancet, The</i> , 2020, 395, 191-199.	6.3	280
34	Impact of established cardiovascular disease on outcomes in the randomized global leaders trial. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 1369-1378.	0.7	6
35	Rationale and design of the British Heart Foundation (BHF) Coronary Microvascular Function and CT Coronary Angiogram (CorCTCA) study. <i>American Heart Journal</i> , 2020, 221, 48-59.	1.2	27
36	Association between post-percutaneous coronary intervention bivalirudin infusion and net adverse clinical events: a post hoc analysis of the GLOBAL LEADERS study. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 22-30.	1.4	7

#	ARTICLE	IF	CITATIONS
37	Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS. <i>European Heart Journal</i> , 2020, 41, 3533-3545.	1.0	93
38	Economic evaluation of culprit lesion only PCI vs. immediate multivessel PCI in acute myocardial infarction complicated by cardiogenic shock: the CULPRIT-SHOCK trial. <i>European Journal of Health Economics</i> , 2020, 21, 1197-1209.	1.4	4
39	Redefining Adverse and Reverse Left Ventricular Remodeling by Cardiovascular Magnetic Resonance Following ST-Segment Elevation Myocardial Infarction and Their Implications on Long-Term Prognosis. <i>Circulation: Cardiovascular Imaging</i> , 2020, 13, e009937.	1.3	24
40	Comparative Significance of Invasive Measures of Microvascular Injury in Acute Myocardial Infarction. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e008505.	1.4	37
41	Low-Dose Alteplase During Primary Percutaneous Coronary Intervention According to Ischemic Time. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1406-1421.	1.2	16
42	A randomized controlled trial of a physiology-guided percutaneous coronary intervention optimization strategy: Rationale and design of the TARGET FFR study. <i>Clinical Cardiology</i> , 2020, 43, 414-422.	0.7	13
43	One-Year Outcomes After Low-Dose Intracoronary Alteplase During Primary Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e008855.	1.4	5
44	Genetic dysregulation of endothelin-1 is implicated in coronary microvascular dysfunction. <i>European Heart Journal</i> , 2020, 41, 3239-3252.	1.0	73
45	Effects of Intracoronary Alteplase on Microvascular Function in Acute Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2020, 9, e014066.	1.6	11
46	Intravascular Imaging and 12-Month Mortality After Unprotected Left Main Stenosis PCI. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 346-357.	1.1	70
47	Outcomes Associated with Respiratory Failure for Patients with Cardiogenic Shock and Acute Myocardial Infarction: A Substudy of the CULPRIT-SHOCK Trial. <i>Journal of Clinical Medicine</i> , 2020, 9, 860.	1.0	8
48	Ticagrelor With or Without Aspirin in High-Risk Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2403-2413.	1.2	60
49	Ticagrelor With or Without Aspirin After Complex PCI. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2414-2424.	1.2	122
50	Fractional Flow Reserve-Based Coronary Artery Bypass Surgery. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 1086-1096.	1.1	32
51	Percutaneous coronary intervention versus medical therapy in patients with angina and grey-zone fractional flow reserve values: a randomised clinical trial. <i>Heart</i> , 2020, 106, 758-764.	1.2	13
52	Evaluation and Management of Nonculprit Lesions in STEMI. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 1145-1154.	1.1	33
53	Continuous intracoronary versus standard intravenous infusion of adenosine for fractional flow reserve assessment: the HYPEREMIC trial. <i>EuroIntervention</i> , 2020, 16, 560-567.	1.4	4
54	Low-dose intracoronary alteplase during primary percutaneous coronary intervention in patients with acute myocardial infarction: the T-TIME three-arm RCT. <i>Efficacy and Mechanism Evaluation</i> , 2020, 7, 1-86.	0.9	0

#	ARTICLE	IF	CITATIONS
55	Current Smoking and Prognosis After Acute ST-Segment Elevation Myocardial Infarction. <i>JACC: Cardiovascular Imaging</i> , 2019, 12, 993-1003.	2.3	46
56	Invasive Versus Medical Management in Patients With Prior Coronary Artery Bypass Surgery With a Non-ST Segment Elevation Acute Coronary Syndrome. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007830.	1.4	17
57	Percutaneous coronary intervention versus coronary artery bypass grafting in patients with three-vessel or left main coronary artery disease: 10-year follow-up of the multicentre randomised controlled SYNTAX trial. <i>Lancet, The</i> , 2019, 394, 1325-1334.	6.3	406
58	Ticagrelor with or without Aspirin in High-Risk Patients after PCI. <i>New England Journal of Medicine</i> , 2019, 381, 2032-2042.	13.9	683
59	Predictors of segmental myocardial functional recovery in patients after an acute ST-Elevation myocardial infarction. <i>European Journal of Radiology</i> , 2019, 112, 121-129.	1.2	16
60	Predictive factors of discordance between the instantaneous wave-free ratio and fractional flow reserve. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 94, 356-363.	0.7	49
61	Revascularisation and mechanical circulatory support in patients with ischaemic cardiogenic shock. <i>Heart</i> , 2019, 105, 1364-1374.	1.2	3
62	Sex-based associations with microvascular injury and outcomes after ST-segment elevation myocardial infarction. <i>Open Heart</i> , 2019, 6, e000979.	0.9	7
63	Prognostic Value and Risk Continuum of Noninvasive Fractional Flow Reserve Derived from Coronary CT Angiography. <i>Radiology</i> , 2019, 292, 343-351.	3.6	89
64	The Potential Use of the Index of Microcirculatory Resistance to Guide Stratification of Patients for Adjunctive Therapy in Acute Myocardial Infarction. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 951-966.	1.1	25
65	A protocol update of the Fractional Flow Reserve versus Angiography for Multivessel Evaluation (FAME) 3 trial: A comparison of fractional flow reserve-guided percutaneous coronary intervention and coronary artery bypass graft surgery in patients with multivessel coronary artery disease. <i>American Heart Journal</i> , 2019, 214, 156-157.	1.2	10
66	Diastolic pressure ratio: new approach and validation vs. the instantaneous wave-free ratio. <i>European Heart Journal</i> , 2019, 40, 2585-2594.	1.0	44
67	Combining mathematical modelling with in vitro experiments to predict in vivo drug-eluting stent performance. <i>Journal of Controlled Release</i> , 2019, 303, 151-161.	4.8	28
68	Predictive ability of ACEF and ACEF II score in patients undergoing percutaneous coronary intervention in the GLOBAL LEADERS study. <i>International Journal of Cardiology</i> , 2019, 286, 43-50.	0.8	19
69	50% Ischaemia and No Obstructive Coronary Artery Disease (INOCA): prevalence and predictors of coronary vasomotion disorders. , 2019, , .		0
70	Ischemia and No Obstructive Coronary Artery Disease. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e008126.	1.4	107
71	Circumferential Strain Predicts Major Adverse Cardiovascular Events Following an Acute ST-Segment Elevation Myocardial Infarction. <i>Radiology</i> , 2019, 290, 329-337.	3.6	32
72	Effect of Low-Dose Intracoronary Alteplase During Primary Percutaneous Coronary Intervention on Microvascular Obstruction in Patients With Acute Myocardial Infarction. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 56.	3.8	88

#	ARTICLE	IF	CITATIONS
73	MINOCA: Requirement for Definitive Diagnostic Work-Up. Heart Lung and Circulation, 2019, 28, e4-e6.	0.2	3
74	Ischaemic Heart Disease. , 2019, , 355-363.		0
75	Intravascular ultrasound assessment of the effects of rotational atherectomy in calcified coronary artery lesions. International Journal of Cardiovascular Imaging, 2018, 34, 1365-1371.	0.7	17
76	Rationale and design of the British Heart Foundation (BHF) Coronary Microvascular Angina (CorMicA) stratified medicine clinical trial. American Heart Journal, 2018, 201, 86-94.	1.2	22
77	Coronary microvascular dysfunction in patients with stable coronary artery disease: The CE-MARC 2 coronary physiology sub-study. International Journal of Cardiology, 2018, 266, 7-14.	0.8	41
78	Arterial Access for Invasive Coronary Angiography: The "Left Backhand"™. Heart Lung and Circulation, 2018, 27, e98-e99.	0.2	2
79	Persistent Iron Within the Infarct Core After ST-Segment Elevation Myocardial Infarction. JACC: Cardiovascular Imaging, 2018, 11, 1248-1256.	2.3	43
80	Rationale and design of the Coronary Microvascular Angina Cardiac Magnetic Resonance Imaging (CorCMR) diagnostic study: the CorMicA CMR sub-study. Open Heart, 2018, 5, e000924.	0.9	12
81	Access Site and Outcomes for Unprotected Left Main Stem Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2018, 11, 2480-2491.	1.1	12
82	Systemic microvascular dysfunction in microvascular and vasospastic angina. European Heart Journal, 2018, 39, 4086-4097.	1.0	139
83	Stratified Medical Therapy Using Invasive Coronary Function Testing in Angina. Journal of the American College of Cardiology, 2018, 72, 2841-2855.	1.2	436
84	Coronary Thermodilution Waveforms After Acute Reperfused ST-Segment Elevation Myocardial Infarction: Relation to Microvascular Obstruction and Prognosis. Journal of the American Heart Association, 2018, 7, e008957.	1.6	5
85	Prognostic Value of the Residual SYNTAX Score After Functionally Complete Revascularization in ACS. Journal of the American College of Cardiology, 2018, 72, 1321-1329.	1.2	40
86	Five-Year Outcomes with PCI Guided by Fractional Flow Reserve. New England Journal of Medicine, 2018, 379, 250-259.	13.9	622
87	Single Versus 2 Stent Strategies for Coronary Bifurcation Lesions: A Systematic Review and Meta-Analysis of Randomized Trials With Long-Term Follow-Up. Journal of the American Heart Association, 2018, 7, .	1.6	53
88	Sex Differences in Adenosine-Free Coronary Pressure Indexes. JACC: Cardiovascular Interventions, 2018, 11, 1454-1463.	1.1	12
89	Hypertension, Microvascular Pathology, and Prognosis After an Acute Myocardial Infarction. Hypertension, 2018, 72, 720-730.	1.3	33
90	Effect of remote ischaemic preconditioning on coronary artery function in patients with stable coronary artery disease. , 2018, , .		0

#	ARTICLE	IF	CITATIONS
91	1â€¦Coronary microvascular dysfunction in stable coronary artery disease: the CE-MARC 2 coronary physiology sub-study. , 2018, , .		0
92	One-Year Outcomes after PCI Strategies in Cardiogenic Shock. <i>New England Journal of Medicine</i> , 2018, 379, 1699-1710.	13.9	303
93	Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. <i>Lancet, The</i> . 2018. 392. 940-949.	6.3	555
94	Validation of a novel non-hyperaemic index of coronary artery stenosis severity: the Resting Full-cycle Ratio (VALIDATE RFR) study. <i>EuroIntervention</i> , 2018, 14, 806-814.	1.4	157
95	Culotte stenting for coronary bifurcation lesions with 2nd and 3rd generation everolimus-eluting stents: the CELTIC Bifurcation Study. <i>EuroIntervention</i> , 2018, 14, e318-e324.	1.4	16
96	Meta-Analysis of the Index of Microvascular Resistance in Acute STEMI Using Incomplete Data. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 421-422.	1.1	1
97	Validation of the â€œsmartâ€-minimum FFR Algorithm in an unselected all comer population of patients with intermediate coronary stenoses. <i>International Journal of Cardiovascular Imaging</i> , 2017, 33, 991-997.	0.7	3
98	Complete Immediate Revascularization of the Patient With ST-Segmentâ€“Elevation Myocardial Infarction Is the New Standard of Care. <i>Circulation</i> , 2017, 135, 1571-1573.	1.6	6
99	Time is still muscle and there is still room for improvement. <i>Heart</i> , 2017, 103, 96-97.	1.2	0
100	Is Delayed Stenting of the Culprit Artery in Patients With STEMI Ever Worth the Wait? â€“. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2805-2807.	1.2	2
101	Diagnostic Accuracy of 3.0â€“T Magnetic Resonance T1 and T2 Mapping and T2â€“Weighted Darkâ€“Blood Imaging for the Infarctâ€“Related Coronary Artery in Nonâ€“STâ€“Segment Elevation Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	15
102	Reduced duration of dual antiplatelet therapy using an improved drug-eluting stent for percutaneous coronary intervention of the left main artery in a real-world, all-comer population: Rationale and study design of the prospective randomized multicenter IDEAL-LM trial. <i>American Heart Journal</i> , 2017, 187, 104-111.	1.2	11
103	Comparison of Characteristics and Complications in Men Versus Women Undergoing Chronic Total Occlusion Percutaneous Intervention. <i>American Journal of Cardiology</i> , 2017, 119, 535-541.	0.7	35
104	PCI Strategies in Patients with Acute Myocardial Infarction and Cardiogenic Shock. <i>New England Journal of Medicine</i> , 2017, 377, 2419-2432.	13.9	764
105	Meta-Analysis of Death and Myocardial Infarction in the DEFINE-FLAIR and iFR-SWEDEHEART Trials. <i>Circulation</i> , 2017, 136, 2389-2391.	1.6	32
106	Agreement of the Resting Distal to Aortic Coronary Pressure With the Instantaneous Wave-Free Ratio. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2105-2113.	1.2	43
107	Influence of Contrast Media Dose and Osmolality on the Diagnostic Performance of Contrast Fractional Flow Reserve. <i>Circulation: Cardiovascular Interventions</i> , 2017, 10, .	1.4	8
108	Protocol for an economic evaluation of the randomised controlled trial of culprit lesion only PCI versus immediate multivessel PCI in acute myocardial infarction complicated by cardiogenic shock: CULPRIT-SHOCK trial. <i>BMJ Open</i> , 2017, 7, e014849.	0.8	1

#	ARTICLE	IF	CITATIONS
109	Safety and Efficacy of Polymer-Free Biolimus A9â€œCoated Versus Bare-Metal Stents in Orally Anticoagulated Patients. JACC: Cardiovascular Interventions, 2017, 10, 1633-1642.	1.1	11
110	Accuracy of Fractional Flow Reserve Measurements in Clinical Practice. JACC: Cardiovascular Interventions, 2017, 10, 1392-1401.	1.1	49
111	Persistence of Infarct Zone T2 Hyperintensity at 6 Months After Acute ST-Segmentâ€œElevation Myocardial Infarction. Circulation: Cardiovascular Imaging, 2017, 10, .	1.3	16
112	Comparison of Different Diastolic Restingâ€œIndexes to iFR. Journal of the American College of Cardiology, 2017, 70, 3088-3096.	1.2	163
113	Radial Versus Femoral Access for Rotational Atherectomy. Circulation: Cardiovascular Interventions, 2017, 10, .	1.4	14
114	Infarct size and left ventricular remodelling after preventive percutaneous coronary intervention. Heart, 2016, 102, 1980-1987.	1.2	11
115	Remote Zone Extracellular Volume and Left Ventricular Remodeling in Survivors of ST-Elevation Myocardial Infarction. Hypertension, 2016, 68, 385-391.	1.3	44
116	Temporal Evolution of Myocardial Hemorrhage and Edema in Patients After Acute STâ€œSegment Elevation Myocardial Infarction: Pathophysiological Insights and Clinical Implications. Journal of the American Heart Association, 2016, 5, .	1.6	96
117	â€œWaves of Edemaâ€œSeem Implausible. Journal of the American College of Cardiology, 2016, 67, 1868-1869.	1.2	5
118	Continuum of Vasodilator Stress Fromâ€œRest to Contrast Medium toâ€œAdenosine Hyperemia for Fractionalâ€œFlow Reserve Assessment. JACC: Cardiovascular Interventions, 2016, 9, 757-767.	1.1	129
119	Coronary bifurcation lesions treated with simple or complex stenting: 5-year survival from patient-level pooled analysis of the Nordic Bifurcation Study and the British Bifurcation Coronary Study. European Heart Journal, 2016, 37, 1923-1928.	1.0	103
120	Influence of access site choice for cardiac catheterization on risk of adverse neurological events: A systematic review and meta-analysis. American Heart Journal, 2016, 181, 107-119.	1.2	40
121	The EBC TWO Study (European Bifurcation Coronary TWO). Circulation: Cardiovascular Interventions, 2016, 9, .	1.4	102
122	Discordance Between Resting and Hyperemic Indices of Coronary Stenosis Severity. Circulation: Cardiovascular Interventions, 2016, 9, .	1.4	67
123	The Influence of Lesion Location on the Diagnostic Accuracy of Adenosine-Free Coronary Pressure Wire Measurements. JACC: Cardiovascular Interventions, 2016, 9, 2390-2399.	1.1	81
124	Comparative Prognostic Utility of Indexes of Microvascular Function Alone or in Combination in Patients With an Acute ST-Segmentâ€œElevation Myocardial Infarction. Circulation, 2016, 134, 1833-1847.	1.6	135
125	Percutaneous coronary angioplasty versus coronary artery bypass grafting in treatment of unprotected left main stenosis (NOBLE): a prospective, randomised, open-label, non-inferiority trial. Lancet, The, 2016, 388, 2743-2752.	6.3	620
126	115â€œ...Persistence of Infarct Zone Oedema at 6 Months after Acute ST-elevation Myocardial Infarction: Incidence, Pathophysiology and Association with Left Ventricular Remodelling. Heart, 2016, 102, A81.2-A81.	1.2	0

#	ARTICLE	IF	CITATIONS
127	133â€¦Although CT Coronary Angiography in the West of Scotland is Used in a Higher Risk Population than Recommended by Nice, The Rate of Subsequent Invasive Coronary Angiography is Lower than in the Promise and Scot-Heart Studies. <i>Heart</i> , 2016, 102, A95-A95.	1.2	0
128	114â€¦Persistence of Haemoglobin Degradation Products within Infarct Scar Tissue after ST-elevation Myocardial Infarction: Incidence, Correlates and Implications for Left Ventricular Remodelling. <i>Heart</i> , 2016, 102, A81.1-A81.	1.2	0
129	2â€¦Coronary flow reserve and index of microvascular resistance in acute stemi. <i>Heart</i> , 2016, 102, A1.2-A1.	1.2	0
130	The relationship between oxidised LDL, endothelial progenitor cells and coronary endothelial function in patients with CHD. <i>Open Heart</i> , 2016, 3, e000342.	0.9	12
131	Urine proteomics in the diagnosis of stable angina. <i>BMC Cardiovascular Disorders</i> , 2016, 16, 70.	0.7	20
132	Myocardial Hemorrhage After Acute Reperfused ST-Segmentâ€Elevation Myocardial Infarction. <i>Circulation: Cardiovascular Imaging</i> , 2016, 9, e004148.	1.3	158
133	Prognostic significance of infarct core pathology revealed by quantitative non-contrast in comparison with contrast cardiac magnetic resonance imaging in reperfused ST-elevation myocardial infarction survivors. <i>European Heart Journal</i> , 2016, 37, 1044-1059.	1.0	105
134	Microvascular (Dys)Function and Clinical Outcome in Stable Coronary Disease. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1170-1172.	1.2	27
135	Multivessel versus culprit lesion only percutaneous revascularization plus potential staged revascularization in patients with acute myocardial infarction complicated by cardiogenic shock: Design and rationale of CULPRIT-SHOCK trial. <i>American Heart Journal</i> , 2016, 172, 160-169.	1.2	93
136	Safety of guidewire-based measurement of fractional flow reserve and the index of microvascular resistance using intravenous adenosine in patients with acute or recent myocardial infarction. <i>International Journal of Cardiology</i> , 2016, 202, 305-310.	0.8	20
137	Microvascular resistance of the culprit coronary artery in acute ST-elevation myocardial infarction. <i>JCI Insight</i> , 2016, 1, e85768.	2.3	39
138	Fractional flow reserve (FFR) versus angiography in guiding management to optimise outcomes in non-ST segment elevation myocardial infarction (FAMOUS-NSTEMI) developmental trial: cost-effectiveness using a mixed trial- and model-based methods. <i>Cost Effectiveness and Resource Allocation</i> , 2015, 13, 19.	0.6	14
139	Impact of treatment algorithms on the prescribing of antithrombotic therapy in patients with suspected acute coronary syndrome â€ a prospective audit. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 1176-1184.	1.1	0
140	Outcomes following implantation of the biolimus A9â€eluting Bio<sc>M</sc>atrix coronary stent: Primary analysis of the eâ€<sc>B</sc>io<sc>M</sc>atrix registry. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 86, 1151-1160.	0.7	13
141	Physiological assessment of coronary lesion severity. <i>Coronary Artery Disease</i> , 2015, 26, e8-e14.	0.3	2
142	110â€¦Infarct Burden Following Multivessel PCI Vs. Infarct-Only PCI in Patients with Acute Stemi: The Glasgow Prami CMR Sub-Study: Abstract 110 Table 1. <i>Heart</i> , 2015, 101, A63.1-A63.	1.2	0
143	Fractional flow reserve-guided management in stable coronary disease and acute myocardial infarction: recent developments. <i>European Heart Journal</i> , 2015, 36, 3155-3164.	1.0	58
144	Reducing In-Stent Restenosis. <i>Journal of the American College of Cardiology</i> , 2015, 65, 2314-2327.	1.2	95

#	ARTICLE	IF	CITATIONS
145	Integrated Physiologic Assessment of Ischemic Heart Disease in Real-World Practice Using Index of Microcirculatory Resistance and Fractional Flow Reserve. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, e002857.	1.4	89
146	Dual antiplatelet response during PCI: VerifyNow P2Y12 predicts myocardial necrosis and thromboxane B2 generation confirms wide variation in aspirin response. <i>Thrombosis Research</i> , 2015, 135, 1140-1146.	0.8	3
147	Invasive assessment of the coronary microcirculation in the catheter laboratory. <i>International Journal of Cardiology</i> , 2015, 199, 141-149.	0.8	12
148	Outcomes of Percutaneous Coronary Intervention Performed at Offsite Versus Onsite Surgical Centers in the United Kingdom. <i>Journal of the American College of Cardiology</i> , 2015, 66, 363-372.	1.2	22
149	Pathophysiology of LV Remodeling in Survivors of STEMI. <i>JACC: Cardiovascular Imaging</i> , 2015, 8, 779-789.	2.3	116
150	Repeatability of Fractional Flow Reserve Despite Variations in Systemic and Coronary Hemodynamics. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 1018-1027.	1.1	83
151	Current frontiers in the clinical research of coronary physiology. <i>Interventional Cardiology</i> , 2015, 7, 97-108.	0.0	0
152	Variation in thromboxane B2 concentrations in serum and plasma in patients taking regular aspirin before and after clopidogrel therapy. <i>Platelets</i> , 2015, 26, 17-24.	1.1	10
153	Polymer-free Drug-Coated Coronary Stents in Patients at High Bleeding Risk. <i>New England Journal of Medicine</i> , 2015, 373, 2038-2047.	13.9	672
154	Rationale and design of the Fractional Flow Reserve versus Angiography for Multivessel Evaluation (FAME) 3 Trial: A comparison of fractional flow reserve-guided percutaneous coronary intervention and coronary artery bypass graft surgery in patients with multivessel coronary artery disease. <i>American Heart Journal</i> , 2015, 170, 619-626.e2.	1.2	58
155	Fractional flow reserve versus angiography for guidance of PCI in patients with multivessel coronary artery disease (FAME): 5-year follow-up of a randomised controlled trial. <i>Lancet</i> , The, 2015, 386, 1853-1860.	6.3	455
156	Assessment of Fractional Flow Reserve in Patients With Recent Non-ST-Segment Elevation Myocardial Infarction. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, e002207.	1.4	17
157	Fractional flow reserve vs. angiography in guiding management to optimize outcomes in non-ST-segment elevation myocardial infarction: the British Heart Foundation FAMOUS-NSTEMI randomized trial. <i>European Heart Journal</i> , 2015, 36, 100-111.	1.0	241
158	Five-year outcomes of staged percutaneous coronary intervention in the SYNTAX study. <i>EuroIntervention</i> , 2015, 10, 1402-1408.	1.4	9
159	Will this trial change my practice? TOTAL: a randomised trial of thrombus aspiration in ST-elevation myocardial infarction. <i>EuroIntervention</i> , 2015, 11, 361-363.	1.4	3
160	High-bolus dose tirofiban compared with abciximab in primary percutaneous coronary intervention: a propensity score-matched outcome study. <i>EuroIntervention</i> , 2015, 10, 1187-1194.	1.4	5
161	Is Hyperaemia Essential for Accurate Functional Assessment of Coronary Stenosis Severity?. <i>Interventional Cardiology Review</i> , 2015, 10, 72.	0.7	0
162	Does Routine Pressure Wire Assessment Influence Management Strategy at Coronary Angiography for Diagnosis of Chest Pain?. <i>Circulation: Cardiovascular Interventions</i> , 2014, 7, 248-255.	1.4	205

#	ARTICLE	IF	CITATIONS
163	Impact of left ventricular function in relation to procedural outcomes following percutaneous coronary intervention: insights from the British Cardiovascular Intervention Society. <i>European Heart Journal</i> , 2014, 35, 3004-3012.	1.0	65
164	Response to Letter Regarding Article, "Prognostic Value of the Index of Microcirculatory Resistance Measured After Primary Percutaneous Coronary Intervention". <i>Circulation</i> , 2014, 129, e342.	1.6	0
165	A Randomized Trial of Deferred Stenting Versus Immediate Stenting to Prevent No- or Slow-Reflow in Acute ST-Segment Elevation Myocardial Infarction (DEFER-STEMI). <i>Journal of the American College of Cardiology</i> , 2014, 63, 2088-2098.	1.2	204
166	Three-Year Results Comparing Platinum-Chromium PROMUS Element and Cobalt-Chromium XIENCE V Everolimus-Eluting Stents in De Novo Coronary Artery Narrowing (from the PLATINUM Trial). <i>American Journal of Cardiology</i> , 2014, 113, 1117-1123.	0.7	37
167	Adenosine. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 581-591.	1.1	214
168	Multicenter Core Laboratory Comparison of the Instantaneous Wave-Free Ratio and Resting P ₁ /P ₂ With Fractional Flow Reserve. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1253-1261.	1.2	301
169	Fractional flow reserve derived from coronary CT angiography: Variation of repeated analyses. <i>Journal of Cardiovascular Computed Tomography</i> , 2014, 8, 307-314.	0.7	45
170	Fractional Flow Reserve-Guided PCI for Stable Coronary Artery Disease. <i>New England Journal of Medicine</i> , 2014, 371, 1208-1217.	13.9	905
171	Outcomes in Patients With ST-Segment Elevation Acute Myocardial Infarction Treated With Clopidogrel Versus Prasugrel (from the INFUSE-AMI Trial). <i>American Journal of Cardiology</i> , 2014, 113, 1457-1460.	0.7	35
172	Comprehensive Dobutamine Stress CMR Versus Echocardiography in LBBB and Suspected Coronary Artery Disease. <i>JACC: Cardiovascular Imaging</i> , 2014, 7, 490-498.	2.3	30
173	Fractional flow reserve and the index of microvascular resistance in patients with acute coronary syndromes. <i>EuroIntervention</i> , 2014, 10, T55-T63.	1.4	28
174	VERIFY (VERification of Instantaneous Wave-Free Ratio and Fractional Flow Reserve for the Assessment) Trial. <i>Journal of the American College of Cardiology</i> , 2013, 61, 1421-1427.	1.2	197
175	Randomized Trial of Preventive Angioplasty in Myocardial Infarction. <i>New England Journal of Medicine</i> , 2013, 369, 1115-1123.	13.9	871
176	Fractional flow reserve versus angiography in guiding management to optimize outcomes in non-ST-elevation myocardial infarction (FAMOUS-NSTEMI): Rationale and design of a randomized controlled clinical trial. <i>American Heart Journal</i> , 2013, 166, 662-668.e3.	1.2	11
177	The Impact of Coronary Bifurcation Stenting Strategy on Health-Related Functional Status. <i>JACC: Cardiovascular Interventions</i> , 2013, 6, 139-145.	1.1	8
178	The Role of Cardiac Magnetic Resonance Imaging (MRI) in Acute Myocardial Infarction (AMI). <i>Heart Lung and Circulation</i> , 2013, 22, 243-255.	0.2	31
179	Quality of life following percutaneous coronary interventions in octogenarians: a systematic review. <i>Heart</i> , 2013, 99, 779-784.	1.2	15
180	Usefulness of Fractional Flow Reserve to Improve Diagnostic Efficiency in Patients With Non-ST Elevation Myocardial Infarction. <i>American Journal of Cardiology</i> , 2013, 111, 45-50.	0.7	21

#	ARTICLE	IF	CITATIONS
181	Vasodilatory Capacity of the Coronary Microcirculation is Preserved in Selected Patients With Nonâ€“ST-Segmentâ€“Elevation Myocardial Infarction. <i>Circulation: Cardiovascular Interventions</i> , 2013, 6, 231-236.	1.4	103
182	Prognostic Value of the Index of Microcirculatory Resistance Measured After Primary Percutaneous Coronary Intervention. <i>Circulation</i> , 2013, 127, 2436-2441.	1.6	316
183	TRANSCATHETER AORTIC VALVE IMPLANTATION FOR SEVERE AORTIC STENOSIS: THE COST-EFFECTIVENESS CASE FOR INOPERABLE PATIENTS IN THE UNITED KINGDOM. <i>International Journal of Technology Assessment in Health Care</i> , 2013, 29, 12-19.	0.2	20
184	Succinobucolâ€“eluting stents increase neointimal thickening and periâ€“strut inflammation in a porcine coronary model. <i>Catheterization and Cardiovascular Interventions</i> , 2013, 81, 698-708.	0.7	12
185	TRANSCATHETER AORTIC VALVE IMPLANTATION FOR SEVERE AORTIC STENOSIS: THE COST-EFFECTIVENESS CASE FOR INOPERABLE PATIENTS IN THE UNITED KINGDOM â€“ CORRIGENDUM. <i>International Journal of Technology Assessment in Health Care</i> , 2013, 29, 112-112.	0.2	0
186	Microvascular Resistance Predicts Myocardial Salvage and Infarct Characteristics in STâ€“Elevation Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2012, 1, e002246.	1.6	80
187	Myocardial Repair and Regeneration: Bone Marrow or Cardiac Stem Cells?. <i>Molecular Therapy</i> , 2012, 20, 1102-1105.	3.7	15
188	Clinical outcomes following radial versus femoral artery access in primary or rescue percutaneous coronary intervention in Scotland: retrospective cohort study of 4534 patients. <i>Heart</i> , 2012, 98, 552-557.	1.2	45
189	CMR versus SPECT for diagnosis of coronary heart disease. <i>Lancet, The</i> , 2012, 379, 2145.	6.3	7
190	Fractional Flow Reserveâ€“Guided PCI versus Medical Therapy in Stable Coronary Disease. <i>New England Journal of Medicine</i> , 2012, 367, 991-1001.	13.9	2,248
191	The effect of reactive oxygen species on whole blood aggregation and the endothelial cell-platelet interaction in patients with coronary heart disease. <i>Thrombosis Research</i> , 2012, 130, 210-215.	0.8	25
192	Primary Endpoint Results of the EVOLVE Trial. <i>Journal of the American College of Cardiology</i> , 2012, 59, 1362-1370.	1.2	188
193	Instantaneous Wave-Free Ratio or Fractional Flow Reserve Without Hyperemia. <i>Journal of the American College of Cardiology</i> , 2012, 59, 1916-1917.	1.2	9
194	Prevention of coronary in-stent restenosis and vein graft failure: Does vascular gene therapy have a role?. , 2012, 136, 23-34.		25
195	Use of troponin to diagnose periprocedural myocardial infarction: effect on composite endpoints in the British Bifurcation Coronary Study (BBC ONE). <i>Heart</i> , 2012, 98, 1431-1435.	1.2	12
196	Simple or Complex Stenting for Bifurcation Coronary Lesions. <i>Circulation: Cardiovascular Interventions</i> , 2011, 4, 57-64.	1.4	152
197	Elective percutaneous coronary intervention in the elderly patient. <i>Aging Health</i> , 2011, 7, 271-281.	0.3	3
198	Clinical value of antiplatelet therapy in patients with acute coronary syndromes and in percutaneous coronary intervention. <i>Biomarkers in Medicine</i> , 2011, 5, 9-30.	0.6	3

#	ARTICLE	IF	CITATIONS
199	Perioperative and long-term outcomes following aortic valve replacement: a population cohort study of 4124 consecutive patients. <i>European Journal of Cardio-thoracic Surgery</i> , 2011, 40, 1508-14.	0.6	10
200	Bright-Blood T2-Weighted MRI Has Higher Diagnostic Accuracy Than Dark-Blood Short Tau Inversion Recovery MRI for Detection of Acute Myocardial Infarction and for Assessment of the Ischemic Area at Risk and Myocardial Salvage. <i>Circulation: Cardiovascular Imaging</i> , 2011, 4, 210-219.	1.3	99
201	Low serum cortisol predicts early death after acute myocardial infarction. <i>Critical Care Medicine</i> , 2010, 38, 973-975.	0.4	24
202	The Index of Microcirculatory Resistance Measured Acutely Predicts the Extent and Severity of Myocardial Infarction in Patients With ST-Segment Elevation Myocardial Infarction. <i>JACC: Cardiovascular Interventions</i> , 2010, 3, 715-722.	1.1	161
203	Percutaneous Coronary Intervention in the Elderly. <i>Circulation: Cardiovascular Interventions</i> , 2010, 3, 341-345.	1.4	63
204	Randomized Trial of Simple Versus Complex Drug-Eluting Stenting for Bifurcation Lesions. <i>Circulation</i> , 2010, 121, 1235-1243.	1.6	478
205	Obesity paradox in a cohort of 4880 consecutive patients undergoing percutaneous coronary intervention. <i>European Heart Journal</i> , 2010, 31, 222-226.	1.0	197
206	Randomized Comparison of Percutaneous Coronary Intervention With Coronary Artery Bypass Grafting in Diabetic Patients. <i>Journal of the American College of Cardiology</i> , 2010, 55, 432-440.	1.2	421
207	Angiographic Versus Functional Severity of Coronary Artery Stenoses in the FAME Study. <i>Journal of the American College of Cardiology</i> , 2010, 55, 2816-2821.	1.2	1,077
208	Fractional Flow Reserve Versus Angiography for Guiding Percutaneous Coronary Intervention in Patients With Multivessel Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2010, 56, 177-184.	1.2	990
209	Validation of Magnetic Resonance Myocardial Perfusion Imaging With Fractional Flow Reserve for the Detection of Significant Coronary Heart Disease. <i>Circulation</i> , 2009, 120, 2207-2213.	1.6	191
210	Radial versus femoral approach for high-speed rotational atherectomy. <i>Catheterization and Cardiovascular Interventions</i> , 2009, 74, 550-554.	0.7	53
211	Effect of clopidogrel discontinuation at 1 year after drug eluting stent placement on soluble CD40L, P-selectin and C-reactive protein levels: DECADES (Discontinuation Effect of Clopidogrel After Drug) Trial. <i>Thrombosis and Haemostasis</i> , 2010, 110, 410-417.	1.0	16
212	Drug-eluting stents: A study of international practice. <i>American Heart Journal</i> , 2009, 158, 576-584.	1.2	14
213	Fractional Flow Reserve versus Angiography for Guiding Percutaneous Coronary Intervention. <i>New England Journal of Medicine</i> , 2009, 360, 213-224.	13.9	3,510
214	Three-year clinical outcome of percutaneous treatment of bifurcation lesions in multivessel coronary artery disease with the sirolimus-eluting stent: insights from the Arterial Revascularisation Therapies Study, part II (ARTS II). <i>EuroIntervention</i> , 2009, 5, 190-196.	1.4	17
215	Pharmacological options for inducing maximal hyperaemia during studies of coronary physiology. <i>Catheterization and Cardiovascular Interventions</i> , 2008, 71, 198-204.	0.7	87
216	Validity of self-reported smoking status: Comparison of patients admitted to hospital with acute coronary syndrome and the general population. <i>Nicotine and Tobacco Research</i> , 2008, 10, 861-866.	1.4	45

#	ARTICLE	IF	CITATIONS
217	Hospital and operator variations in drug-eluting stent use: a multi-level analysis of 5967 consecutive patients in Scotland. <i>Journal of Public Health</i> , 2008, 30, 186-193.	1.0	10
218	Smoke-free Legislation and Hospitalizations for Acute Coronary Syndrome. <i>New England Journal of Medicine</i> , 2008, 359, 482-491.	13.9	640
219	Drug-Eluting Stents Versus Bare-Metal Stents for Off-Label Indications. <i>Circulation: Cardiovascular Interventions</i> , 2008, 1, 45-52.	1.4	16
220	Drug-eluting stents: do the risks really outweigh the benefits?. <i>Heart</i> , 2008, 94, 127-128.	1.2	7
221	Bare-Metal versus Drug-Eluting Coronary Stents. <i>New England Journal of Medicine</i> , 2008, 358, 2516-2518.	13.9	4
222	Pro-healing drug-eluting stents: a role for antioxidants?. <i>Clinical Science</i> , 2008, 114, 265-273.	1.8	15
223	Importance of collateral circulation in coronary heart disease. <i>European Heart Journal</i> , 2007, 28, 278-291.	1.0	118
224	The clinical outcome of percutaneous treatment of bifurcation lesions in multivessel coronary artery disease with the sirolimus-eluting stent: insights from the Arterial Revascularization Therapies Study part II (ARTS II). <i>European Heart Journal</i> , 2007, 28, 433-442.	1.0	113
225	The rise and fall of drug-eluting stents: Time trend analysis in 13647 consecutive patients undergoing percutaneous coronary intervention. <i>American Heart Journal</i> , 2007, 154, e37.	1.2	4
226	Rescue Angioplasty after Failed Thrombolytic Therapy for Acute Myocardial Infarction. <i>New England Journal of Medicine</i> , 2005, 353, 2758-2768.	13.9	436
227	Validation of coronary flow reserve measurements by thermodilution in clinical practice. <i>European Heart Journal</i> , 2004, 25, 219-223.	1.0	128
228	The RITA 3 trial. <i>Lancet</i> , The, 2002, 360, 1974.	6.3	2
229	A clinical and in vitro study on the possible interaction of intravenous nitrates with heparin anticoagulation. <i>Clinical Cardiology</i> , 1994, 17, 658-661.	0.7	7
230	Influence of hyperkalaemia and ischaemia on non-receptor-mediated cardiac electrophysiological effects of naloxone. <i>Cardiovascular Research</i> , 1993, 27, 296-303.	1.8	6
231	Pacing termination of spontaneous ventricular tachycardia in the coronary care unit. <i>International Journal of Cardiology</i> , 1992, 36, 223-226.	0.8	6
232	Effects of early captopril administration on infarct expansion, left ventricular remodeling and exercise capacity after acute myocardial infarction. <i>American Journal of Cardiology</i> , 1991, 68, 713-718.	0.7	90
233	Free radical activity during percutaneous trans-luminal coronary angioplasty. <i>Biochemical Society Transactions</i> , 1990, 18, 1183-1184.	1.6	9
234	Dissecting aneurysm of a right-sided descending aorta with a left-sided aortic arch. <i>International Journal of Cardiology</i> , 1988, 18, 271-274.	0.8	2